SGLT2 inhibitors natriuretic effect may contribute to cardiorenal benefits by inhibiting the myocardial sodium–proton exchanger, which has been shown to reduce cardiac hypertrophy and heart failure [74]. Here, SLC5A2 is linked to heart failure.